NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Knight Therapeutics Inc. (GUD.TO) Stock Analysis

Knight Therapeutics Inc. (GUD.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

GUD.TO

CA$11.70

+CA$0.25 (+2.18%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GUD.TO with… →

GUD.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$11.45
Previous Close
CA$11.45
Day's Range
11.34–11.71
52-Week Range
5.66–11.71
Volume
70.51K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.01
Valuation
Market Cap
CA$1.15B
P/E Ratio
78.00
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
45.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.10
EPS (ttm)Profit attributable to each share over the last twelve months.
0.15
Financials (FY)
Revenue (FY)
CA$450.09M+21.22%
Net Income (FY)
−CA$5.37M−224.05%
Profit marginThe share of revenue left as profit after all costs and taxes.
2.72%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
98.23M
1-Year Return
+99.66%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
83.24K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GUD.TO closed at CA$11.70, +99.66% over 1 year.

Knight Therapeutics Inc. (GUD.TO) has a market capitalization of CA$1.15B.

In fiscal 2025, GUD.TO reported revenue of CA$450.09M.

GUD.TO Stock Return by Calendar Year

Knight Therapeutics Inc. (GUD.TO) 10-year return: what CA$10,000 became

1 year
CA$10,000 CA$19,966
+99.66%
5 years
CA$10,000 CA$21,910
+119.10%
10 years
CA$10,000 CA$13,102
+31.02%

If you had invested CA$10,000 in Knight Therapeutics Inc. (GUD.TO) 10 years ago, at the close on October 21, 2016, it would have been worth CA$13,102 at the close on October 21, 2026: +31.02% in total, +2.74% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+93.39%
2025+13.30%
2024+2.89%
2023+0.19%
2022−2.26%
2021−0.93%
2020−29.42%
2019−1.43%
2018−7.46%
2017−22.63%
2016 (partial year)+28.62%

As of October 21, 2026.

GUD.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$450.09M−CA$5.37M−1.2%
2024CA$371.30MCA$4.33M1.2%
2023CA$328.20M−CA$16.84M−5.1%
2022CA$293.56M−CA$29.89M−10.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$450.09MCA$200.23M−CA$2.35M−CA$5.37M−1.2%
2024CA$371.30MCA$174.41MCA$7.40MCA$4.33M1.2%
2023CA$328.20MCA$152.65MCA$6.37M−CA$16.84M−5.1%
2022CA$293.56MCA$138.06M−CA$17.06M−CA$29.89M−10.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GUD.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricGUD.TODrug Manufacturers - Specialty & Generic medianvs median
P/E78.0020.313.8x the median
P/S ratio2.102.100% above
Profit margin2.72%−8.14%10.9 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Knight Therapeutics Inc. (GUD.TO) is capitalised at CA$1.15B on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 830 employees.

GUD.TO last closed at CA$11.70 on October 21, 2026. That is +CA$0.25 (+2.18%) against the previous close. The 52-week range on file runs from CA$5.66 to CA$11.71. The latest close sits 106.71% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$450.09M. Against the prior fiscal year total of CA$371.30M, that is a change of +21.22%. The same year closed with a net loss of CA$5.37M. Profit margin runs at 2.72%. That is 10.9 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are 0.15.

Across the 4 fiscal years on file, revenue moves from CA$293.56M in 2022 to CA$450.09M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 78. That is 3.8 times the Drug Manufacturers - Specialty & Generic median of 20.31. The forward P/E on file is 45. The price-to-sales ratio is 2.1. On price-to-sales that is 0% above the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at −0.01. Daily returns over the trailing 10 years annualize to a volatility of 24.41%. Over the trailing twelve months the total return is +99.66%. Across 10 years the annualized return works out at +2.74%.

Growth & Income

The record shows no dividend for GUD.TO.

The strongest complete calendar year on file is 2025 at +13.30%; the weakest is 2020 at −29.42%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is +93.39%.

Peer Comparison

Knight Therapeutics Inc. (GUD.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Knight Therapeutics Inc. GUD.TO CA$1.15B 78.0
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Knight Therapeutics Inc. trades at a P/E of 78.0.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Knight Therapeutics Inc.

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Visit website →